SCHEMBL21595331

SCHEMBL21595331

C=CCC1CC2(CC1=O)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 2/20 0.37
CRBN Q96SW2 2/20 0.37
NR1H2 P55055 1/20 0.35
EHMT2 Q96KQ7 1/20 0.34
OXTR P30559 1/20 0.34
AVPR1A P37288 1/20 0.34
KDM4E B2RXH2 2/20 0.34
EPHX2 P34913 1/20 0.34
RORC P51449 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ACACB O00763 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
FAAH O00519 1/20 0.32
KRAS P01116 1/20 0.32
GPR183 P32249 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31392323 0.80 NR1H2 (0.41) NR1H2EHMT2OXTRAVPR1AKDM4E
SCHEMBL21595277 0.80 FAAH (0.37) FAAH
SCHEMBL16568475 0.76 NR1H2 (0.40) DDB1CRBNNR1H2KDM4ERORC
SCHEMBL2723574 0.76 NR1H2 (0.40) DDB1CRBNNR1H2KDM4ERORC
SCHEMBL29737454 0.76 NR1H2 (0.40) DDB1CRBNNR1H2KDM4ERORC
SCHEMBL21595319 0.76 NR1H2 (0.35) DDB1CRBNNR1H2EHMT2OXTR
SCHEMBL2253382 0.74 DDB1 (0.41) DDB1CRBNNR1H2KDM4EMAPT
SCHEMBL2253385 0.74 DDB1 (0.41) DDB1CRBNNR1H2KDM4EMAPT
SCHEMBL21595372 0.74 GRIN2B (0.39) DDB1CRBNKDM4EMAPTTHRB
SCHEMBL29172705 0.73 NR1H2 (0.40) DDB1CRBNNR1H2EHMT2OXTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3810615-B1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-01-28 EP disclosed
US-11274111-B2 Arginase inhibitors and methods of use MERCK SHARP & DOHME CORP. (US) 2022-03-15 US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2021-06-03 US disclosed
EP-3810615-A1 ARGINASE INHIBITORS AND METHODS OF USE Merck Sharp & Dohme Corp. (US) 2021-04-28 EP disclosed
WO-2019245890-A1 ARGINASE INHIBITORS AND METHODS OF USE MERCK SHARP & DOHME CORP. (US) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210163505-A1 ARGINASE INHIBITORS AND METHODS OF USE ARG1, ARG2, PRMT1 DDB1 3556/4885CRBN 2891/4885NR1H2 97/4885
US-11274111-B2 Arginase inhibitors and methods of use ARG1, ARG2, PRMT1 DDB1 3556/4885CRBN 2891/4885NR1H2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.